COPD triple therapy treatment guidelines: Are you up-to-date?

To help you navigate the latest national guidelines we have provided you with a summary of the recommendations when treating moderate-to-severe patients with COPD:

NICE COPD treatment guidelines

From July 2019, NICE COPD treatment guidance recommends triple therapy for patients with COPD who are on dual therapy and have either day-to-day symptoms that adversely impact quality of life or, have had 1 severe or 2 moderate exacerbations within a year.¹

Whilst NICE did not make a specific recommendation around whether an ICS/LABA/LAMA treatment should be delivered in multiple inhalers or a single inhaler they did comment as follows:

From the economic evidence, using a single inhaler device was more cost effective¹

Minimise the number of inhalers and different types of inhalers used by each person where possible¹

NICE recommendations are for classes of medicine, they do not recommend Trelegy Ellipta specifically.

LAMAs and LAMA/LABAs are indicated as maintenance bronchodilator treatments to relieve symptoms in adult patients with COPD
AnoroEllipta (umeclidinium bromide/vilanterol) SmPC. Spiolto Respimat SmPC. Ultibro Breezhaler SmPC. Incruse Ellipta (umeclidinium) SmPC. Seebri Breezhaler SmPC)

Patients on LAMA/LABA who have day-to-day symptoms adversely impacting their quality of life NICE recommends a 3 month trial with ICS/LABA/LAMA and if no improvement to revert to LAMA/LABA.¹

NICE COPD guidelines algorithm

Would you like to see the full NICE COPD treatment guidelines?

Footnotes

ICS, inhaled corticosteroid; LABA, long-acting ß₂-agonist; LAMA, long-acting muscarinic antagonist

Trelegy Ellipta OD is indicated for maintenance treatment in adult patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an ICS and a LABA, or a combination of a LAMA and a LABA.²

Trelegy Ellipta is generally well tolerated. Common adverse reactions include: headache, nasopharyngitis, influenza, upper respiratory tract infection, pneumonia, back pain, rhinitis, cough, pharyngitis, arthralgia, sinusitis, oropharyngeal pain, bronchitis, constipation, candidiasis of mouth and throat, urinary tract infection.²

In common with other corticosteroid-containing medicines, there is an increased risk of pneumonia in patients with COPD treated with Trelegy Ellipta.²

References:

  1. https://www.nice.org.uk/guidance/ng115/ (Last accessed: May 2020)
  2. Trelegy Ellipta SmPC.

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.

© 2020 GSK Group of Companies or its licensor
Trademarks are the property of their respective owners
Trelegy Ellipta was developed in collaboration with

PM-GB-FVU-WCNT-200010 | July 2020